Study guide

13.1 Clinical Review Process

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

13.1 Clinical Review Process

Key Takeaways Explain This Topic AI

Clinical review is a structured check that medicines still match goals of therapy, patient status, and safety—not a one-off list of drugs.

Drug-related problems include unnecessary drug, wrong drug, dose too low or high, adverse drug reaction, adherence failure, and clinically important interactions.

Prioritise problems by risk of harm and clinical urgency, then agree a collaborative plan with the patient and prescriber.

Home Medicines Review (HMR) and residential medication management review models illustrate structured, collaborative review at awareness level for interns.

Document findings, recommendations, and follow-up; monitoring without action or documentation is incomplete care under Standard 3.3.

Last updated: August 2026

12.1 Clinical Review Process

Quick Answer: Clinical review under Standard 3.3 is a structured, repeated process : confirm goals of therapy , compare the current regimen with those goals and the patient’s clinical status, identify drug-related problems (DRPs) , prioritise by harm and urgency, agree a collaborative plan , and set follow-up . In Australia this may be informal (every dispense and counselling encounter) or formal (for example Home Medicines Review or residential medication management review pathways at awareness level for interns).

Passing the Intern Written Examination requires more than listing medicines. You must show you can monitor and evaluate whether therapy is still appropriate—efficacy, safety, adherence, and fit with the patient’s goals—and know what to do when it is not.

Why structured review matters

Medicines change over time: indications resolve, renal function declines, new diagnoses appear, adherence drifts, and interactions accumulate. A “once correct” regimen can become unnecessary, under-dosed, over-dosed, poorly tolerated, or unsafe . Structured review reduces the risk that you only notice problems when a crisis presents at the counter.

Clinical review is not the same as:

  • Dispensing completeness checks (legal particulars, quantity, schedule)—necessary, but not full review
  • Counselling at supply alone—education without reassessing goals and outcomes is incomplete
  • Computer interaction alerts alone —software flags possibilities; the pharmacist judges clinical relevance

It is the professional process of asking: For this person, with these goals, is this medicine list still the right plan—and if not, what should change?

Steps of a structured medication review

Use a repeatable sequence so nothing critical is skipped under exam time pressure.

1. Establish context and goals of therapy

Clarify why each medicine is used and what success looks like. Goals may be curative (finish antibiotics for confirmed infection), disease-modifying (HFrEF pillars), symptom control (analgesia, reflux), prevention (statin, antiplatelet, vaccination), or substitution (opioid agonist therapy). Goals should be patient-centred : blood pressure targets, symptom relief, fall reduction, fertility plans, cultural priorities, and what the person values most.

Without goals you cannot judge “dose too low” or “unnecessary drug.” A proton pump inhibitor continued years after a short gastro-protection indication may no longer match any active goal—unless a new indication has appeared.

2. Collect a best-possible medication history

Reconcile prescribed, over-the-counter, complementary, and “as needed” medicines, including inhalers, patches, injectables, and samples. Note doses, formulations, timing, recent changes, and who is managing administration (patient, carer, dose administration aid). Cross-check allergies, adverse reaction history, adherence patterns, and recent hospital discharge lists. Discrepancies between hospital discharge and community supply are classic DRP sources.

3. Assess clinical status and monitoring data

Link the regimen to symptoms, signs, and available results : blood pressure, heart rate, weight, glucose readings, eGFR, electrolytes, INR, HbA1c, LFTs, drug levels, and red-flag symptoms (chest pain, severe dyspnoea, suicidal ideation, severe rash, black stools). Trends matter more than isolated numbers when available (see Section 13.2).

4. Identify drug-related problems systematically

Work through a standard DRP framework so categories are not missed:

DRP category Core question Exam-level examples

Unnecessary drug Is there a valid current indication? Duplicate NSAID + OTC ibuprofen; PPI without ongoing need; antibiotic for viral URTI

Wrong drug Is this the preferred/effective/safe choice for this patient? Non-selective beta-blocker in poorly controlled asthma when alternatives exist; teratogenic agent if pregnancy possible

Dose too low Is exposure inadequate for the goal? Subtherapeutic antibiotic duration/dose; antidepressant at starting dose for months without review when partial response expected

Dose too high Is exposure excessive for age, organ function, or goal? Digoxin without renal adjustment; high-dose opioid for mild pain

Adverse drug reaction (ADR) Is harm likely drug-related? ACEI cough; statin myalgia; clozapine agranulocytosis risk signals

Adherence / administration Is the medicine being taken as intended and usable? Complex multi-dose regimen; costly co-payment barriers; inhaler technique failure

Interactions Do drug–drug, drug–disease, or drug–food pairs change risk/benefit? Macrolide + high-dose statin; warfarin–amiodarone; NSAID in heart failure

Also consider missing therapy (indication present, no medicine or non-drug care) as a related gap—for example no statin after established atherosclerotic disease when not contraindicated, or no rescue inhaler with preventer-only asthma regimens when indicated by guidelines and history.

5. Prioritise problems

You will rarely fix everything in one encounter. Prioritise by:

Immediate safety risk (bleeding on over-anticoagulation, hyperkalaemia with ACEI + spironolactone + renal impairment, anaphylaxis risk, serotonin toxicity cluster)

High potential harm if delayed (uncontrolled severe hypertension with end-organ symptoms, untreated severe infection signs, suicidal risk on antidepressants)

  • Efficacy gaps affecting major outcomes (non-adherence to secondary prevention after ACS)
  • Quality-of-life and preference issues (side effects driving non-adherence, regimen complexity)
  • Lower-risk optimisation (formulation switches for convenience when stable)

Document urgency and what can safely wait for the next GP or specialist review.

6. Agree a collaborative plan

Recommendations may include dose change, switch, stop (with taper if needed), add monitoring, refer, or reinforce non-drug care. Involve the patient (goals, capacity, preferences) and the prescriber when prescription medicines change. Interns and pharmacists practise within scope: some actions are counselling and OTC optimisation; others require prescriber agreement. Communicate using situation, assessment, recommendation structure and be ready to justify with AMH/APF-aligned reasoning (restricted open-book on exam day).

7. Implement, document, and follow up

Record DRPs identified, advice given, prescriber contacts, and monitoring due dates. Set a review interval appropriate to risk (days for INR after interacting antibiotic; weeks for antidepressant response; months for stable lipids). Closing the loop is part of Standard 3.3—not optional paperwork.

Goals of therapy in practice

Make goals specific and measurable where possible:

Hypertension: achieve individualised BP target while minimising falls, electrolyte disturbance, and renal deterioration

Type 2 diabetes: balance glycaemic targets with hypoglycaemia risk, cardiorenal benefit of modern agents, and patient capacity

  • Pain: functional goals (sleep, mobility) rather than “zero pain at any opioid cost”
  • Anticoagulation: prevent stroke/VTE while keeping bleeding risk acceptable and INR/DOAC use appropriate

When goals conflict (aggressive HbA1c vs hypoglycaemia in frailty), explicit prioritisation with the patient and team is the professional response—not silent default to a single number.

Home Medicines Review and residential review (awareness level)

Interns are not expected to run full funded review programmes from memory of every item number, but should understand the clinical model :

Home Medicines Review (HMR) concepts: collaborative, usually GP-referred process where an accredited pharmacist reviews medicines in the home context, identifies DRPs, and reports recommendations to the referrer for shared decision-making.

Residential medication management review concepts: structured review for people in residential aged care, where polypharmacy, transitions of care, swallowing/administration issues, and high-risk medicines are common.

Both models emphasise collaboration, documentation, and follow-up , not a one-way letter. Community and hospital pharmacists also perform continuous micro-reviews at every supply and ward round; formal programmes extend depth when complexity or transitions warrant it.

Putting it together for the exam

Expect scenarios that ask you to spot the highest-priority DRP , choose the next best action (clarify history, contact prescriber, counsel, urgent referral), or select which problem is unnecessary drug vs dose too low vs adherence . Anchor every answer to goals → assessment → prioritised plan → monitoring . Structured review is how Standard 3.3 turns a medicine list into safe, person-centred care.